ESC 2026: Aficamten breaks new ground in nonobstructive HCM
This year at the European Society of Cardiology (ESC) Scientific Sessions, findings from the ACACIA-HCM trial explored the effect of…
Cardiovascular
-
-
ESC 2026: Evolocumab explores new frontiers in CV disease prevention
This year at the European Society of Cardiology (ESC) Scientific Sessions, new findings were presented from a pre-specified analysis of…
-
Updated UK guidance for finerenone introduces new treatment for HF patients
The National Institute for Health and Care Excellence (NICE) in the UK recently published new guidance on the usage of…
-
Bayer’s heart failure drug bound for NHS on NICE recommendation
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bayer’s non-steroidal heart failure drug, Kerendia (finerenone), for…
-
ACC 2026: Baxdrostat lowers BP in uncontrolled hypertension
At the 2026 American College of Cardiology (ACC) Scientific Session in New Orleans, researchers presented a meta-analysis of randomized trials…
-
JPM26: Pfizer’s Metsera deal supercharges its obesity strategy
Pfizer is gearing up for a consumer-driven obesity drug market, drawing parallels to the demand surge it experienced with the…
-
AHA 2025: semaglutide 2.4mg lowers cardiovascular risk in SCORE-HF Study
On 10 November at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana, data from the SCORE-HF…
-
Affinia raises $40m for gene therapy development
Gene therapy company Affinia Therapeutics has raised $40m in a Series C funding round, led by New Enterprise Associates (NEA).…
-
Amgen’s Phase III data supports FDA label expansion of Repatha
Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug…
-
Mabwell and Aditum launch Kalexo Bio for siRNA therapy development
China’s Mabwell Bioscience and US-based Aditum Bio have launched Kalexo Bio, a new company, to develop a new small interfering…
